Shareholder letterhttps://promisneurosciences.com/wp-content/uploads/2020/08/CEO-memo-to-ProMIS-shareholders.aug_.11.2020.pdf
A concise summary of the company ALZ pipeline. Little mention of other areas. Not much analysis of the investor value proposition that should be the focus of a letter to shareholders. Hopefully Zacks analysts can pick up the slack and explain how much revenue we might expect and when.
I've gleaned $2-6 dollars in licensing revenue per diagnostic test, but I do not know the number of potential tests annually or the split between PMN and BCNI.
It would be great to see some significant revenues by December.